ABCL - AbCellera Biologics Inc Stock Price, Fair Value and News

$3.50+0.04 (+1.16%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ABCL Price Action

Last 7 days

-3.8%

Last 30 days

-34.8%

Last 90 days

-15.9%

Trailing 12 Months

20.3%

ABCL RSI Chart

ABCL Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-6.1

Price/Sales (Trailing)

29.66

EV/EBITDA

-4.6

Price/Free Cashflow

-6.84

ABCL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

35.3M

Rev. Growth (Yr)

37.62%

Rev. Growth (Qtr)

-47.58%

ABCL Earnings

Earnings (TTM)

-171.7M

Earnings Growth (Yr)

-11.76%

Earnings Growth (Qtr)

-64.48%

ABCL Profitability

EBT Margin

-580.14%

Return on Equity

-17.81%

Return on Assets

-12.66%

Free Cashflow Yield

-14.61%

ABCL Investor Care

Shares Dilution (1Y)

1.34%

Diluted EPS (TTM)

-0.57

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	23.1M	32.9M	35.3M	0
2024	35.8M	33.1M	33.0M	28.8M
2023	373.6M	261.7M	149.9M	38.0M
2022	489.0M	507.3M	603.2M	485.4M
2021	431.2M	447.7M	443.8M	375.2M
2020	67.0M	122.4M	177.8M	233.2M
2019	0	0	0	11.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CEO	Dr. Carl L.G. Hansen Ph.D.
WEBSITE	abcellera.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	590

AbCellera Biologics Inc Frequently Asked Questions

What is the ticker symbol for AbCellera Biologics Inc? What does ABCL stand for in stocks?

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbCellera Biologics Inc (ABCL)?

As of Wed Dec 03 2025, market cap of AbCellera Biologics Inc is 1.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers.

Is AbCellera Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ABCL is over valued or under valued. Whether AbCellera Biologics Inc is cheap or expensive depends on the assumptions which impact AbCellera Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABCL.

What is AbCellera Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ABCL's PE ratio (Price to Earnings) is -6.1 and Price to Sales (PS) ratio is 29.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.